David Loebenberg - Concepedia

Author

David Loebenberg

The University of Texas Health Science Center at San Antonio

Also Known As

D Loebenberg, D. LOEBENBERG, D. Loebenberg, DAVID LOEBENBERG, David Loebenberg

131

Publications

6.5K

Citations

H-Index

Concepts

All Affiliations

The University of Texas Health Science Center at San Antonio Murphy Oil Corporation (United States)Cubist Pharmaceuticals (United States)Bloomfield College

About

David Loebenberg is an author at The University of Texas Health Science Center at San Antonio specializing in medicine, pharmacology, and microbiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	24	856
2	Health Sciences	8	8	288
3	Engineering	4	4	70
4	Natural Sciences	3	3	52
5	Allergy	2	2	121

David Loebenberg

Publications

6.4K

Citations

H-Index

Page 1

	Year	Citations
Nonfilamentous C. albicans Mutants Are Avirulent Hsiu‐Jung Lo, Julia R. Köhler, Beth DiDomenico, Cell BiologyUnicellular OrganismMicrobiology	1997	1.8K
In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts F. Sabatelli, Rutul Patel, Paul A. Mann, Antimicrobial Agents and Chemotherapy	2006	485
Three-Dimensional Models of Wild-Type and Mutated Forms of Cytochrome P450 14α-Sterol Demethylases from <i>Aspergillus fumigatus</i> and <i>Candida albicans</i> Provide Insights into Posaconazole Binding Xiao Li, Vincent Madison, Andrew S. Chau, Antimicrobial Agents and Chemotherapy	2004	266
Application of Real-Time Quantitative PCR to Molecular Analysis of <i>Candida albicans</i> Strains Exhibiting Reduced Susceptibility to Azoles Andrew S. Chau, Cara Mendrick, F. Sabatelli, Antimicrobial Agents and Chemotherapy	2004	187
Mutations in <i>Aspergillus fumigatus</i> Resulting in Reduced Susceptibility to Posaconazole Appear To Be Restricted to a Single Amino Acid in the Cytochrome P450 14α-Demethylase Paul A. Mann, Raulo Parmegiani, Shui-Qing Wei, Antimicrobial Agents and Chemotherapy	2003	185
In Vivo Activity of Posaconazole against<i>Mucor</i>spp. in an Immunosuppressed-Mouse Model Qiu N. Sun, Laura K. Najvar, Rosie Bocanegra, Antimicrobial Agents and Chemotherapy	2002	183
Activities of the Triazole Derivative SCH 56592 (Posaconazole) against Drug-Resistant Strains of the Protozoan Parasite <i>Trypanosoma</i> ( <i>Schizotrypanum</i> ) <i>cruzi</i> in Immunocompetent and Immunosuppressed Murine Hosts Judith Molina, Olindo Assis Martins-Filho, Z. Brener, Antimicrobial Agents and Chemotherapy	2000	182
Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated Candidiasis David R. Andes, Karen Marchillo, R. Conklin, Antimicrobial Agents and Chemotherapy	2003	177
Antiproliferative Effects and Mechanism of Action of SCH 56592 against <i>Trypanosoma</i> ( <i>Schizotrypanum</i> ) <i>cruzi</i> : In Vitro and In Vivo Studies Julio A. Urbina, Gilberto Payares, Lellys M. Contreras, Antimicrobial Agents and Chemotherapy	1998	162
Activity of Posaconazole in Treatment of Experimental Disseminated Zygomycosis Éric Dannaoui, Jacques F. Meis, David Loebenberg, Antimicrobial Agents and Chemotherapy	2003	159

Page 1